Amphotericin B

Its primary molecular target is ergosterol, a sterol associated with fungal cell membranes. Human membranes instead contain cholesterol, but Amphotericin B can also bind to it, reducing the separation between antifungal action and host toxicity. This difference in sterol preference provides useful antifungal selectivity, although the selectivity is incomplete and clinically important adverse effects can result.

After binding to ergosterol, Amphotericin B disrupts the organized barrier formed by the fungal cell membrane. Pore formation compromises membrane integrity, so the cell can no longer maintain its normal membrane-dependent functions. The resulting structural failure explains why the drug is fungicidal rather than merely suppressing fungal growth, which is important during treatment of severe infections.

Cholesterol is present in human membranes, so binding beyond the fungal target can affect host tissues. This interaction helps explain why treatment may produce toxicity, including kidney injury and disturbances in electrolyte balance. The same molecular property that contributes to membrane disruption in fungi therefore creates a therapeutic limitation and requires clinicians to weigh antifungal benefit against harm.

Fungal infections involving the central nervous system create a treatment challenge because effective therapy must address organisms located in infected nervous tissue, not only infection elsewhere in the body. Amphotericin B is therefore relevant when fungal meningitis or another neuroinvasive infection is present. Treatment decisions must balance the need for intensive antifungal activity with the difficulty of reaching the affected site.

It may be used when a fungal infection affects the central nervous system, particularly in serious or life-threatening conditions such as fungal meningitis. Its role is especially important when rapid, intensive therapy is required. In this context, the medication is part of an urgent response to neuroinvasive disease rather than treatment of a limited, nonthreatening fungal infection.

The intended outcome is control of a serious fungal infection that may involve the brain or other central nervous system structures. However, treatment can be accompanied by kidney injury and electrolyte disturbances because the drug can interact with human membranes. These competing outcomes illustrate why therapy requires careful balancing of rapid antifungal treatment against potentially significant systemic toxicity.